Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. - Wikidata - awgldk - TriplyDB

Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe.

Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe.

http://www.wikidata.org/entity/Q36555938

about

Translating pharmacogenomics: challenges on the road to the clinic Systems analysis of high-throughput data Cost-Effectiveness of Pharmacogenomic and Pharmacogenetic Test-Guided Personalized Therapies: A Systematic Review of the Approved Active Substances for Personalized Medicine in Germany Economic Evaluation of Pharmacogenetic Tests in Patients Subjected to Renal Transplantation: A Review of Literature Clinician adoption of genetic testing for drug metabolizing enzymes: is patient safety the low-hanging fruit of personalized medicine?Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: influence on treatment response Towards the clinical implementation of pharmacogenetics in bipolar disorder.Pharmacogenomics and individualized medicine: translating science into practice.Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain Multispectral imaging and pathology: seeing and doing more.Pharmacogenetics and pharmacogenomics of anticancer agents.Pharmacogenomics--how close/far are we to practising individualized medicine for children?Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature.Overview of the pharmacoeconomics of pharmacogenetics.Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice.Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy.Insights into the role of heritable genetic variation in the pharmacokinetics and pharmacodynamics of anticancer drugs.Routine pharmacogenetic testing in clinical practice: dream or reality?Avoiding adverse drug reactions by pharmacogenetic testing: a systematic review of the economic evidence in the case of TPMT and AZA-induced side effects.Recent progress and clinical importance on pharmacogenetics in cancer therapy.Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.Issues surrounding the health economic evaluation of genomic technologies.Global formulary review: how do we integrate pharmacogenomic information?Molecular diagnostics for pharmacogenomic testing of fluoropyrimidine based-therapy: costs, methods and applications.Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism.Interindividual variability in TPMT enzyme activity: 10 years of experience with thiopurine pharmacogenetics and therapeutic drug monitoring.Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions.Pharmacogenetics, cost of genotyping, and guidelines for individualizing therapy with mercaptopurine in pediatric acute lymphoblastic leukemia.Can the pharmacogenetics of GST gene polymorphisms predict the dose of busulfan in pediatric hematopoietic stem cell transplantation?CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies.Ethnic variation of thiopurine S-methyltransferase activity: a large, prospective population study.Assessment of Pharmacogenomic Panel Assay for Prediction of Taxane Toxicities: Preliminary Results.Thiopurine S-methyltransferase (TPMT) activity is better determined by biochemical assay versus genotyping in the Jewish population.Adverse drug reactions and pharmacogenomics: recent advances TPMT testing in azathioprine: a ‘cost-effective use of healthcare resources’?Towards an economic evidence base for pharmacogenetics: consideration of outcomes is key

P2860

Q21092371-63866AC0-976C-4D8E-9A12-25A9BDB3F6C1 Q27023883-71B9D210-6D57-4A5E-B2BC-EF69DCEA8182 Q28072203-12D2953C-4E57-4D2B-B555-EFA82168B624 Q28073025-342C60E3-325E-4C6A-9847-3DB4C580A2A0 Q33626990-12E7CC2F-2129-4E3F-82DC-F4B9816A7BED Q33674158-C188F876-365A-4B64-B58C-9F3E8CBFEAB7 Q33688133-5453B5A9-F875-4EB7-9F01-0B3C122B125D Q34297575-55F980A0-D278-4724-AFC8-7BC91D3092D7 Q34326911-ED63EC3A-BB28-4F7F-B7D3-346F99A2ED2B Q34621288-01D17000-FE26-419B-92A6-34433FBF41AF Q35030489-D84A7362-575C-460B-9A0E-CA9D04B7C276 Q35135951-0CF692F8-67AD-487B-BD73-AA20BDB8C94B Q35890606-1F253678-CB45-4A1E-B4CC-6D7BB0761757 Q36690248-D78810D3-7F79-4F42-A77C-EF5341D47F16 Q36702588-C42AF243-F90E-4B22-B1D0-43ABB65248C8 Q36709301-623A0A4D-74FE-488B-B76F-24765DF15C9F Q36847276-1081E0F7-5AEE-417C-B122-0BDE06F978A7 Q36989859-3D01AD2C-1725-471D-A67D-65AF83933963 Q37207401-74CA6ECE-396C-491C-8AFA-78102BD29860 Q37382559-B9216810-3030-4021-85F1-09E597D8FAB6 Q37502607-F6F3D196-E578-479B-988B-DAEC6AE76D74 Q37541151-24A61762-474A-4867-882B-A45D1949F048 Q37864479-B60D47E8-6FF9-4E0A-8BCC-1320A85E974F Q37866805-9E1E03D3-4E24-4B76-A22E-EF3CE205E996 Q37887337-92010E1A-532B-45B5-B982-95C8871FB028 Q38217625-0166EFA8-69C0-4065-8F26-16EB1040CA9E Q38671676-A03C47EC-7F29-4F12-A544-E0ADEEDEA129 Q38777644-18F48AB4-AE16-4C7A-BE0B-D2ACE9CC6D76 Q42345788-EA81CAE3-F565-4449-BFEF-6D06B54F7B65 Q43248045-128D0778-6F3D-49E3-B119-E2F9A8A4E275 Q44624989-C1C08D77-9E8E-4F28-8ED5-76D91AB615CB Q46730786-71FA4AAD-0433-4496-AB57-7FE09AEBD4C1 Q47157497-A6D72557-7B2B-4058-8691-459AEDD6CAA0 Q50481447-17B9183E-BE63-499D-BA38-7CF10DB5A824 Q57302751-010E9DD7-C12A-4420-9D21-D0E44D5DC3D3 Q57697170-CEBA3613-E34F-4E7F-807D-CA6B79E6C2B3 Q57697517-B9927C3C-BC9D-4C70-8221-39155CC07F1E

P2860

Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe.

http://www.wikidata.org/entity/Q36555938

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Cost-effectiveness of pharmaco ...... phoblastic leukemia in Europe.

@ast

Cost-effectiveness of pharmaco ...... phoblastic leukemia in Europe.

@en

type

label

Cost-effectiveness of pharmaco ...... phoblastic leukemia in Europe.

@ast

Cost-effectiveness of pharmaco ...... phoblastic leukemia in Europe.

@en

prefLabel

Cost-effectiveness of pharmaco ...... phoblastic leukemia in Europe.

@ast

Cost-effectiveness of pharmaco ...... phoblastic leukemia in Europe.

@en

P1433

Q36555938-53F07F1C-09B2-4397-94F4-47B9919ED2B7

P1476

Q36555938-4D1EA790-E11B-4094-A3FF-524B08DEE5D7

P2093

Q36555938-0A62F96F-D449-4F73-BC34-5AB8C1D3935D

Q36555938-29C46BF8-690B-4E3F-A366-B4846448E30A

Q36555938-A508873D-032F-4CB5-B14F-CCEDCD76D329

Q36555938-D411C110-D82A-4DA1-BC60-155D291F4337

Q36555938-ED7C58DE-CABD-45F4-8726-5880A9508ADC

Q36555938-F9F5762D-DF6D-4641-A833-EC4DFD6FF239

P2860

Q36555938-02D64EEB-07A2-4090-8819-33E7E33A9FB7

Q36555938-033356D0-31B8-4539-8196-6A649DFC9DC5

Q36555938-04792683-2E03-49CB-A244-09C6B70915A2

Q36555938-0C6A6350-D09A-4B0A-B535-69850867E28F

Q36555938-3065F010-DA71-4E5F-99E8-701879F1E4E2

Q36555938-390A3A1E-B755-4AE6-AEFD-9A84018309D4

Q36555938-482683F8-87D0-42CE-971F-8E23A2EFEF57

Q36555938-59F496F5-3B7B-45B6-B572-44FA120BB12F

Q36555938-5BA10817-08E4-434B-B7FE-2C31380BE32A

Q36555938-68B5EF51-AB6E-4F9A-AEAC-E6F9B8423374

P304

Q36555938-4267AD79-A3EC-452F-AE21-9D0C6C4E2F6B

P31

Q36555938-2FD045A4-E4BB-4F2C-AA83-D78CE7182288

P356

Q36555938-20E93DB3-07FB-4C43-938E-6452C75FA183

P433

Q36555938-F38C27BA-500A-46DE-B004-E7FB890D03AC

P478

Q36555938-7CEEC08E-6D93-4F88-AAC1-9CD962B37EC0

P50

Q36555938-C36E9748-6CFC-4909-9B22-B20DF7928299

P577

Q36555938-EDF9B945-E614-40F0-857B-41901C2536C1

P698

Q36555938-15EC66BD-D0EE-40F4-A4C3-149F2BCC1877

P921

Q36555938-857ABA4E-4FB8-4930-A67D-459805E21189

Q36555938-C15EADFC-6670-46F2-BD1F-927D256EB9AB

P356

14622416.7.5.783

P1433

Pharmacogenomics

P1476

Cost-effectiveness of pharmaco ...... mphoblastic leukemia in Europe

@en

P2093

Christine M Enzing

http://www.w3.org/2001/XMLSchema#string

David Gurwitz

http://www.w3.org/2001/XMLSchema#string

Dolores Ibarreta

http://www.w3.org/2001/XMLSchema#string

Emma Gutierrez de Mesa

http://www.w3.org/2001/XMLSchema#string

Michael M Hopkins

http://www.w3.org/2001/XMLSchema#string

Symone B Detmar

http://www.w3.org/2001/XMLSchema#string

P2860

A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase

Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients

The clinical impact of thiopurine methyltransferase polymorphisms on thiopurine treatment

Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy.

Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia.

Pharmacogenetics: ethical problems and solutions.

Pharmacogenomics--drug disposition, drug targets, and side effects.

An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics.

Azathioprine: current status and future considerations.

Moving towards individualized medicine with pharmacogenomics.

P304

783-792

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/14622416.7.5.783

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Elske van den Akker-van Marle

P577

2006-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16886902

http://www.w3.org/2001/XMLSchema#string

P921

pharmacogenomics